Aquestive Therapeutics (AQST) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Aquestive Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $3.0M of AQST stock on the open market.
Get emailed when insiders cluster-buy stocks like AQST
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AQST insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $374K | 5 |
| Q2 2026 | — | 0 | $265K | 3 |
| Q1 2026 | — | 0 | $1.7M | 7 |
| Q4 2025 | — | 0 | $686K | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Aquestive Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $3.0M. 11 of 18 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
AQST earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 11, 2026 | +16.6% | Sold $100K | -1.4%S&P -0.1% | +13.0% |
| May 13, 2026 | +1.5% | None | +13.7%S&P +1.4% | -11.8% |
| Mar 4, 2026 | +12.9% | None | +3.4%S&P +0.1% | -3.1% |
| Nov 5, 2025 | -18.8% | Sold $686K | +0.8%S&P -0.7% | +4.1% |
| Aug 11, 2025 | -7.1% | None | -3.1%S&P +0.9% | +31.0% |
| May 12, 2025 | -2.1% | None | -17.9%S&P +4.0% | +44.5% |
| Mar 5, 2025 | -17.8% | None | -5.5%S&P -0.7% | +5.0% |
| Jan 13, 2025 | -15.8% | None | -1.0%S&P +0.3% | +13.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 16SEC | Daniel BarberCEO, President | Sell Plan | 25,000652,317 held (−4%) | $4.82 | $120K | -0.8% | — |
| Sep 11SEC | Sherry KorczynskiChief Commercial Officer | Sell Plan | 8,750235,689 held (−4%) | $5.22 | $46K | -8.4% | — |
| Aug 18SEC | Daniel BarberCEO, President | Sell Plan | 25,000585,574 held (−4%) | $4.29 | $107K | +11.4% | — |
| Jul 17SEC | Daniel BarberCEO, President | Sell Plan | 20,369610,574 held (−3%) | $4.00 | $81K | +19.5% | — |
| Jul 17SEC | Daniel BarberCEO, President | Sell Plan | 4,631630,943 held (−1%) | $4.03 | $19K | +18.6% | — |
| Jun 24SEC | Julie KropDirector | Sell Plan | 25,000 | $5.02 | $126K | -4.8% | — |
| Jun 16SEC | Daniel BarberCEO, President | Sell Plan | 25,000635,574 held (−4%) | $4.16 | $104K | +14.9% | — |
| May 18SEC | Daniel BarberCEO, President | Sell Plan | 8,257660,574 held (−1%) | $4.29 | $35K | +11.4% | — |
| Mar 11SEC | Daniel BarberCEO, President | Sell | 180,6771,004,753 held (−15%) | $4.17 | $753K | +14.6% | — |
| Mar 11SEC | A Ernest Toth Jr.CFO | Sell | 58,254376,112 held (−13%) | $4.17 | $243K | +14.6% | — |
| Mar 11SEC | Cassie JungCOO | Sell | 45,791274,980 held (−14%) | $4.17 | $191K | +14.6% | — |
| Mar 11SEC | Lori J BraenderGeneral Counsel | Sell | 40,102442,879 held (−8%) | $4.17 | $167K | +14.6% | — |
| Mar 11SEC | Peter E. BoydChief People Officer | Sell | 29,814338,509 held (−8%) | $4.17 | $124K | +14.6% | — |
| Mar 11SEC | Melina CioffiSvp, Regulatory Affairs | Sell | 25,311274,867 held (−8%) | $4.17 | $106K | +14.6% | — |
| Mar 11SEC | Sherry KorczynskiChief Commercial Officer | Sell | 15,741241,117 held (−6%) | $4.17 | $66K | +14.6% | — |
| Oct 17SEC | Cassie JungCOO | Sell Plan | 67,575240,771 held (−22%) | $7.01 | $474K | -31.8% | — |
| Oct 17SEC | Carl N KrausChief Medical Officer | Sell Plan | 20,272282,475 held (−7%) | $7.00 | $142K | -31.7% | — |
| Oct 17SEC | Peter E. BoydSee Remarks | Sell Plan | 10,000268,323 held (−4%) | $7.00 | $70K | -31.7% | — |
Insiders at Aquestive Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Daniel BarberCEO, President | — | $1.2M | Sep 16, 2026 | — |
| Cassie JungCOO | — | $665K | Mar 11, 2026 | — |
| A Ernest Toth Jr.CFO | — | $243K | Mar 11, 2026 | — |
| Peter E. BoydChief People Officer | — | $194K | Mar 11, 2026 | — |
| Lori J BraenderGeneral Counsel | — | $167K | Mar 11, 2026 | — |
| Carl N KrausChief Medical Officer | — | $142K | Oct 17, 2025 | — |
| Julie KropDirector | — | $126K | Jun 24, 2026 | — |
| Sherry KorczynskiChief Commercial Officer | — | $111K | Sep 11, 2026 | — |
| Melina CioffiSvp, Regulatory Affairs | — | $106K | Mar 11, 2026 | — |
AQST stock: common questions
Are Aquestive Therapeutics, Inc. insiders buying AQST stock?
In the past 12 months, 0 insiders reported open-market purchases of AQST worth $0.
Are Aquestive Therapeutics, Inc. insiders selling AQST stock?
9 insiders reported sales worth $3.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AQST's 52-week range?
Over the past year AQST has traded between $2.95 and $7.49. It last closed at $4.78 on Oct 9, 2026.